- Home
- ICCM vs GTBP Comparison
ICCM vs GTBP Comparison
Compare ICCM & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ICCM | GTBP |
|---|---|---|
| Founded | 2006 | 1965 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.4M | 17.7M |
| IPO Year | 2013 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ICCM | GTBP |
|---|---|---|
| Price | $3.35 | $0.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 8.8M | 1.3M |
| Earning Date | 05-27-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $139.51 | N/A |
| Revenue Next Year | $75.66 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $0.26 |
| 52 Week High | $9.54 | $2.29 |
Technical Indicators
Market Signals| Indicator | ICCM | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 45.58 | 40.88 |
| Support Level | $0.48 | $0.34 |
| Resistance Level | $5.69 | $0.46 |
| Average True Range (ATR) | 0.34 | 0.04 |
| MACD | -0.28 | -0.01 |
| Stochastic Oscillator | 4.48 | 17.70 |
Price Performance
Historical ComparisonAbout ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.